Skip to content
Skip to content
Anabolicco

Anabolic Steroid Cardiomyopathy: Heart Changes, Symptoms and Care

How anabolic steroid use can relate to cardiomyopathy, heart failure symptoms, cardiac testing, recovery uncertainty and when to seek care.

Anabolic steroid cardiomyopathy refers to heart muscle disease linked to anabolic androgenic steroid exposure. The concern is not just a high blood pressure reading or one abnormal blood test. Steroid exposure may contribute to ventricular enlargement, thickening, weaker pumping, impaired relaxation, rhythm problems and heart failure symptoms that need clinical assessment.

Use emergency care for chest pain, severe breathlessness, fainting, stroke signs, blue lips, confusion, coughing pink froth, or sudden collapse. Do not wait to prove steroids caused the symptom.

What cardiomyopathy means

Cardiomyopathy is disease of the heart muscle. It can make it harder for the heart to pump blood, relax between beats or maintain a safe rhythm. Some people have no early symptoms. Others develop breathlessness, fatigue, swelling, palpitations, chest discomfort or fainting.

AAS associated cardiomyopathy is not diagnosed from steroid history alone. It is a clinical question that combines symptoms, exposure history, examination, ECG, blood tests and cardiac imaging. Other causes such as inherited cardiomyopathy, high blood pressure, coronary disease, valve disease, myocarditis, alcohol, cocaine, methamphetamine, thyroid disease, kidney disease and sleep apnea may need assessment too.

How anabolic steroids may affect the heart muscle

Long term supraphysiologic androgen exposure may affect the heart through blood pressure elevation, lipid changes, increased red blood cell mass, kidney strain, sleep apnea, direct myocardial signalling, fibrosis, hypertrophy and rhythm effects. Training load and body size can also change heart structure, which makes interpretation more complex in strength athletes.

These pathways can overlap. A person may have high blood pressure, low HDL cholesterol, high hematocrit and sleep apnea at the same time as myocardial remodeling. Treating one marker does not prove the heart muscle is safe.

Unregulated products add uncertainty because dose, contents and contaminants may differ from the label. Stimulants, thyroid hormone, growth hormone, fat loss drugs and recreational drugs can add cardiac strain.

What human studies show

A 2026 systematic review and meta analysis of resistance trained athletes reported that AAS users had lower left ventricular ejection fraction and worse global longitudinal strain compared with nonusers. Those measures suggest differences in cardiac structure and function, but they do not predict an individual person’s future course.

A large 2025 cohort study reported higher rates of several cardiovascular outcomes among people identified with AAS use, including cardiomyopathy and heart failure. Observational data cannot prove every mechanism in every person, but the signal supports careful clinical assessment rather than reassurance from fitness level alone.

Case reports and reviews describe people with reduced pumping function, heart failure symptoms and improvement after stopping AAS plus medical treatment in some cases. Case reports are useful warning evidence, but they can overrepresent severe presentations and cannot set a personal recovery timeline.

When symptoms need attention

Tests used in assessment

A clinician may start with history, examination, blood pressure, oxygen level, pulse rhythm and an ECG. Blood tests can include blood count, kidney markers, electrolytes, liver markers, glucose measures, lipids, thyroid testing and cardiac markers when symptoms suggest acute injury or heart failure.

Imaging can include echocardiography to assess chamber size, wall thickness, pumping function, valve findings and estimated pressures. Cardiac MRI may be used in selected cases to assess structure, function, scarring or inflammation. Stress testing, rhythm monitoring, coronary assessment or sleep testing may be chosen based on symptoms and risk.

One normal test does not always end the question. Symptoms, timing, image quality, exercise adaptation, blood pressure and coexposures can change interpretation. Bring prior ECGs, echo reports, MRI reports and lab results with dates and units.

What to tell a clinician

Give a clear timeline: current or past AAS use, start and stop dates, products, approximate amounts if known, oral and injectable forms, source changes, missed doses, stimulants, thyroid hormone, growth hormone, diuretics, fat loss drugs, erectile dysfunction medicines, alcohol, nicotine and recreational drugs. Include prescribed medicines and supplements.

Report chest pain, breathlessness, palpitations, fainting, swelling, snoring, witnessed breathing pauses, reduced exercise capacity, severe headaches, neurologic symptoms and family history of cardiomyopathy, sudden cardiac death, heart failure or early coronary disease. Read how to talk with a doctor about anabolic steroid use for a disclosure checklist.

Cardiomyopathy risk does not sit apart from other cardiovascular issues. High blood pressure can strain the left ventricle. Abnormal lipids can add artery risk. High hematocrit can change blood viscosity and clot concern. Kidney injury can worsen blood pressure and fluid balance.

Use blood pressure monitoring during anabolic steroid use, anabolic steroids and cholesterol, and anabolic steroids, hematocrit and blood clots as companion pages. They cannot replace cardiac assessment when symptoms suggest heart failure or rhythm trouble.

Recovery and uncertainty

Some reported cases improve after AAS cessation and heart failure care, but recovery is not guaranteed. The chance of improvement may depend on duration of exposure, severity, blood pressure, other drugs, sleep apnea, genetics, coronary disease, ongoing use and treatment adherence. Scarring or persistent dysfunction may not fully reverse.

Do not stop prescribed heart medicines because symptoms improve, and do not use nonprescribed diuretics, stimulants or thyroid drugs to manage weight or training. If AAS dependence, withdrawal or low mood is present, care may need endocrine, cardiology, primary care, mental health or addiction support.

Questions to ask

  • Do my symptoms require emergency care today?
  • Which tests assess pumping function, rhythm, valves, coronary risk and fluid status?
  • Could blood pressure, sleep apnea, kidney disease or thyroid products be contributing?
  • Which medicines or substances should I stop, continue or discuss before any change?
  • When should imaging, labs or rhythm checks be repeated?

References

  1. What is cardiomyopathy?. American Heart Association.
  2. Symptoms and diagnosis of cardiomyopathy. American Heart Association.
  3. Heart failure. NHS.
  4. Anabolic androgenic steroids on cardiac structure and function in resistance trained athletes. International Journal of Cardiology, 2026.
  5. Cardiovascular disease in anabolic androgenic steroid users. JACC, 2025.
  6. Anabolic androgenic steroids and cardiomyopathy update. Frontiers in Cardiovascular Medicine, 2023.